Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialHannah Cohen, David Isenberg, Nicola Muirhead et al.|The Lancet Haematology|2016Cited by 404